再発性・転移性嗅神経芽腫：ニボルマブの有効性と安全性の評価

基本情報

NCT ID

NCT07100704

ステータス

募集中

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

14

治験依頼者名

National Cancer Center Hospital East

概要

This trial evaluates the efficacy and safety of nivolumab monotherapy in patients with recurrent or metastatic olfactory neuroblastoma that is difficult to treat with curative intent. Specifically, nivolumab 240 mg will be administered on Day 1 and Day 15 of each cycle, or nivolumab 480 mg will be administered on Day 1 of each cycle, and this will be continued until disease progression. One cycle is 28 days. The decision on which treatment to administer will be made through consultation between the participant in this trial and their attending physician.

対象疾患

介入

依頼者（Sponsor）

実施施設 (2)